Lea Dutta

2.2k total citations
26 papers, 214 citations indexed

About

Lea Dutta is a scholar working on Pulmonary and Respiratory Medicine, Obstetrics and Gynecology and Oncology. According to data from OpenAlex, Lea Dutta has authored 26 papers receiving a total of 214 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 12 papers in Obstetrics and Gynecology and 11 papers in Oncology. Recurrent topics in Lea Dutta's work include Endometrial and Cervical Cancer Treatments (12 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Renal cell carcinoma treatment (6 papers). Lea Dutta is often cited by papers focused on Endometrial and Cervical Cancer Treatments (12 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Renal cell carcinoma treatment (6 papers). Lea Dutta collaborates with scholars based in United States, Japan and Spain. Lea Dutta's co-authors include Vicky Makker, Robert Orlowski, Corina E. Dutcus, Matthew H. Taylor, Toni K. Choueiri, Thomas E. Hutson, Robert J. Motzer, Thomas Powles, Camillo Porta and Viktor Grünwald and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Lea Dutta

23 papers receiving 211 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lea Dutta United States	9	113	89	75	62	38	26	214
Alfred Guirguis United States	9	68 0.6×	62 0.7×	41 0.5×	49 0.8×	53 1.4×	12	213
Erik Asmus United States	6	100 0.9×	29 0.3×	41 0.5×	43 0.7×	39 1.0×	9	179
Justin Harold United States	8	73 0.6×	65 0.7×	30 0.4×	38 0.6×	48 1.3×	18	186
Annick Chevalier-Place France	6	56 0.5×	42 0.5×	48 0.6×	61 1.0×	33 0.9×	7	148
Konstantina Tatsi Greece	6	142 1.3×	120 1.3×	40 0.5×	169 2.7×	65 1.7×	6	329
Jana Drozenová Czechia	8	66 0.6×	26 0.3×	34 0.5×	45 0.7×	49 1.3×	29	202
Eric Rios‐Doria United States	8	33 0.3×	159 1.8×	41 0.5×	104 1.7×	25 0.7×	26	205
Susanne Markmann Germany	8	120 1.1×	59 0.7×	39 0.5×	123 2.0×	40 1.1×	23	305
Ronaldo Lúcio Rangel Costa Brazil	8	45 0.4×	73 0.8×	21 0.3×	63 1.0×	27 0.7×	12	191
Kyle M. Devins United States	9	41 0.4×	38 0.4×	49 0.7×	43 0.7×	66 1.7×	41	195

Countries citing papers authored by Lea Dutta

Since Specialization

Citations

This map shows the geographic impact of Lea Dutta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lea Dutta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lea Dutta more than expected).

Fields of papers citing papers by Lea Dutta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lea Dutta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lea Dutta. The network helps show where Lea Dutta may publish in the future.

Co-authorship network of co-authors of Lea Dutta

This figure shows the co-authorship network connecting the top 25 collaborators of Lea Dutta. A scholar is included among the top collaborators of Lea Dutta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lea Dutta. Lea Dutta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eskander, Ramez N., Jung‐Yun Lee, Domenica Lorusso, et al.. (2025). TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy. Journal of the National Comprehensive Cancer Network. 23(3.5).

Lee, Jung-Yun, Baek‐Yeol Ryoo, Jin Won Kim, et al.. (2024). Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC).. Journal of Clinical Oncology. 42(16_suppl). TPS3169–TPS3169. 1 indexed citations

Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2024). Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146. Journal for ImmunoTherapy of Cancer. 12(1). e007929–e007929. 5 indexed citations

Makker, Vicky, Carol Aghajanian, Allen Lee Cohn, et al.. (2023). A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update. Journal of Clinical Oncology. 41(5). 974–979. 25 indexed citations

Yonemori, Kan, Mayu Yunokawa, Kimio Ushijima, et al.. (2022). Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775. Cancer Science. 113(10). 3489–3497. 17 indexed citations

Colombo, N., Domenica Lorusso, Yong‐Mi Kim, et al.. (2021). 145 Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (Study 309/KEYNOTE-775). INFM-OAR (INFN Catania). A78.1–A78. 2 indexed citations

Colombo, Nicoletta, Domenica Lorusso, A. Casado Herráez, et al.. (2021). 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775). Annals of Oncology. 32. S729–S730. 18 indexed citations

Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2021). 796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111. Annals of Oncology. 32. S760–S760. 1 indexed citations

Makker, Vicky, N. Colombo, Antonio Casado, et al.. (2021). O002/#43 Randomized phase 3 study of lenvatinib plus pembrolizumab for advanced endometrial cancer (aec): subgroup analysis of patients with DNA mismatch repair deficient (DMMR) tumors. A1.2–A2.

10.

Makker, Vicky, Matthew H. Taylor, Ana Oaknin, et al.. (2021). Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab. The Oncologist. 26(9). e1599–e1608. 26 indexed citations

11.

Gaspar, Nathalie, Quentin Campbell‐Hewson, Stefan Bielack, et al.. (2020). 443TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082). Annals of Oncology. 31. S1414–S1415.

12.

Gaspar, Nathalie, Quentin Campbell‐Hewson, Stefan Bielack, et al.. (2020). 1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082). Annals of Oncology. 31. S990–S991. 2 indexed citations

13.

Cruz, Filemon S. Dela, Elizabeth Fox, Jodi A. Muscal, et al.. (2020). A phase I/II study of lenvatinib (LEN) plus everolimus (EVE) in recurrent and refractory pediatric solid tumors, including CNS tumors.. Journal of Clinical Oncology. 38(15_suppl). 10527–10527. 5 indexed citations

14.

Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2020). Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC).. Journal of Clinical Oncology. 38(15_suppl). 6083–6083. 7 indexed citations

15.

Marth, Christian, Christof Vulsteke, M.J. Rubio Pérez, et al.. (2020). ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.. Journal of Clinical Oncology. 38(15_suppl). TPS6106–TPS6106. 8 indexed citations

16.

Grünwald, Viktor, Thomas Powles, Toni K. Choueiri, et al.. (2019). Lenvatinib Plus Everolimus or Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Study Design and Rationale. Future Oncology. 15(9). 929–941. 38 indexed citations

17.

Marth, Christian, Christof Vulsteke, Vicky Makker, et al.. (2019). ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer. Annals of Oncology. 30. v433–v433. 3 indexed citations

18.

Makker, Vicky, Antonio Casado, Carol Aghajanian, et al.. (2019). A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.. Journal of Clinical Oncology. 37(15_suppl). TPS5607–TPS5607. 10 indexed citations

19.

Motzer, Robert J., Viktor Grünwald, Thomas E. Hutson, et al.. (2018). A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 36(6_suppl). TPS706–TPS706. 14 indexed citations

20.

Motzer, Robert J., Viktor Grünwald, Thomas E. Hutson, et al.. (2017). A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology. 35(15_suppl). TPS4595–TPS4595. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact